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A newly identified form of phosphoinositide 3-kinase is
regulated by Gbg subunits and is particularly abundant
in phagocytic leukocytes. It is likely to be intimately
involved in the process by which inflammatory signals
regulate phagocyte activation and is a potential target
for new anti-inflammatory drugs.
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Phagocytic white cells, such as neutrophils, are the body’s
first line of defence. In response to inflammatory signals,
such as chemoattractants, they migrate to a site of
infection where they engulf and degrade foreign cells.
The key player in this process is the NADPH oxidase
complex [1], which uses oxygen to rapidly generate vast
amounts of the free radical superoxide anion (O2–) in what
is described as the ‘respiratory burst’. Phagocytes also
release a variety of proteases in a process of degranulation
which parallels the respiratory burst; these proteases are
activated by metabolites of superoxide. 
The inappropriate activation of phagocytes is implicated
in a variety of chronic and acute inflammatory and
cardiovascular pathologies characterized by local tissue
damage, including asthma, arthritis, reperfusion injury and
restenosis. Many pharmaceutical companies are searching
for specific antagonists of chemoattractant receptors in the
hope that they will control phagocyte migration or
activation, but the degree of redundancy between these
receptors is unclear and so the efficacy of such an
approach remains to be seen. An alternative approach is to
target the shared intracellular signalling pathways which
are activated by virtually all chemotactic receptors in
neutrophils, monocytes, eosinophils and basophils.
Chemoattactants and bacterial peptides activate the
phagocyte by binding to G-protein-coupled receptors,
typified by the receptors for the bacterial chemotactic
peptide f-Met–Leu–Phe or the chemokine, interleukin-8
(IL-8). These activated receptors cause dissociation of
heterotrimeric G-proteins to form active Gα–GTP and a
Gβγ dimer. Members of the Gαi family of heterotrimeric
G proteins are highly expressed in phagocytes and play an
important role, as the respiratory burst is attenuated by
pertussis toxin, a specific inhibitor of receptor–Gi/Go
interactions. 
But what signalling components act downstream of the
activated G proteins? The processes of phagocytosis,
superoxide production and degranulation require highly
organized membrane fusion events, and enzymes that
metabolize membrane phospholipids to generate second
messengers have therefore attracted particular attention.
This is especially true of phosphoinositide 3-kinase (PI 3-
kinase), which phosphorylates phosphatidylinositol-4,5-
bisphosphate (PI(4,5)P2) to yield PI(3,4,5)P3 (reviewed in
[2]). PI 3-kinase is intimately involved in phagocyte activa-
tion, as drugs that inhibit the enzyme, such as wortmannin
or LY294002, completely block the superoxide burst [3,4].
There are, however, multiple forms of PI 3-kinase in cells,
and drugs such as wortmannin or LY294002 unfortunately
inhibit all forms of the enzyme, to a greater or lesser
extent. Given the role of the canonical PI 3-kinases in cell
survival and cell growth [5], such drugs may therefore be
quite toxic in vivo. From a drug discovery standpoint, all
that is needed as a promising target is a unique PI 3-
kinase that has a novel mode of regulation — and there-
fore of inhibition — and that is abundant in phagocytes!
Stephens et al. [6] have now reported the purification and
cloning of a Gβγ-stimulated PI 3-kinase which exhibits
just these properties.
The first PI 3-kinase to be cloned was found to consist of a
regulatory subunit, p85, and a catalytic subunit, p110
(reviewed in [7]). Two isoforms of the catalytic subunit —
p110α and p110β — and several regulatory subunits —
p55α, p55PIK, p85α and p85β — have been cloned so far.
Most is known about the p85 regulatory subunits, which
contain several well-known domain types — an SH3
domain, a Bcr-related region and two SH2 domains —
consistent with their presumed role in coupling a catalytic
p110 subunit to a tyrosine kinase. The SH2 domains bind
in a sequence-specific manner to phosphorylated tyrosine
residues in activated receptor and non-receptor tyrosine
kinases. The p110 catalytic subunit associates with p85 via
its amino-terminus, which binds to a region between the
SH2 domains of p85 called the inter-SH2 domain [7].
The p85 subunit regulates the p110 subunit in several
ways. In unstimulated cells, PI 3-kinase is mainly in the
cytosol. Activation of a receptor tyrosine kinase causes
recruitment of p85 to the receptor, thereby translocating
the p110 catalytic subunit to the plasma membrane, where
its substrate, PI(4,5)P2, is found. In addition, the binding
of p85 SH2 domains to an appropriately phosphorylated
receptor causes a conformational change which is trans-
duced to the catalytic subunit, causing activation.
PI 3-kinase in phagocytes was first described by Traynor-
Kaplan et al., in a study of f-Met–Leu–Phe-stimulated
neutrophils [8]. Several observations suggested that this
enzyme was distinct from the canonical p85–p110 form.
First, the phagocyte PI 3-kinase was stimulated by ago-
nists, such as ATP, that activate G-protein-coupled
receptors rather than receptor tyrosine kinases. Second,
the activity in phagocytes was inhibited by pertussis toxin
but was insensitive to the kinase inhibitors genistein or
staurosporine [9], and exhibited a reduced sensitivity to
wortmannin [10]. Third, the phagocyte PI 3-kinase could
be stimulated by Gbg subunits but not by tyrosine-phos-
phorylated peptides that activate p85–p110, and could
not be found in anti-p85 immunoprecipitates [10].
Finally, compared to the slow and sustained activation
induced by factors that induce the p85–p110 enzyme, the
increase in PI(3,4,5)P3 levels in response to f-
Met–Leu–Phe or ATP was rapid and transient, suggest-
ing distinct modes of regulation [9,11]. These
observations suggested the existence in phagocytes of a
unique form of PI 3-kinase, and the race was on to clone
the new enzyme.
In 1995, Stoyanov et al. [12] cloned a cDNA for a novel
p110-related enzyme by homology to conserved regions of
p110α and p110β. This new PI 3-kinase, called p110γ,
could be activated by Gβγ but was also stimulated by
Gα–GTP, in contrast to reports on the partially purified
enzyme from neutrophils [10]. Furthermore, the activation
by Gβγ was very weak compared to the partially purified
preparations [10]. Clearly something was missing. The
missing piece to this puzzle has now dropped into place,
with the purification and cloning of a Gβγ-stimulated PI 3-
kinase activity from pig neutrophils, a tightly-associated
dimer of two subunits, p101 and p120 [6]. Cloning of these
subunits showed that p120, which binds wortmannin, is
highly homologous to the p110γ catalytic subunit [12] —
so similar that it has been renamed p110γ — but signifi-
cant Gβγ stimulation requires the associated regulatory
subunit, p101 [6]. The small activation of isolated p110γ
by Gβγ observed previously [12] probably reflects effects
of the detergents used to store Gβγ on the lipid micelle
mix used to assay PI 3-kinase activity.
The p110γ subunit is clearly distinct from p110α and
p110β. These catalytic subunits are most similar in their
carboxy-terminal kinase domain (homology region 1), but
there is also significant sequence overlap in the PI 3-
kinase-specific homology regions 2 and 3, the function of
which remains unclear. All three isoforms contain a Ras-
binding domain [13], and preliminary data indicate that
co-expression of activated Ras can augment the Gβγ stim-
ulation of p101–p110γ in COS cells (L. Stephens, personal
communication). As expected, p110γ does not show any
homology to the amino-terminal p85-binding site of
p110α/p110β and does not bind to p85 [6,12].
The p101 subunit is something of a ‘black box’ in struc-
tural terms, as it does not show any homology or structural
similarity to any proteins in the database [6]. By analogy
with the canonical p85–p110 enzyme, there are likely to
be discrete regions on both p101 and p110γ which mediate
their interactions, but it is not yet clear whether the Gβγ
subunits bind to p101 or p110γ (see below). Stoyanov et al.
[12] reported that the amino-terminus of p110γ shows
some homology to the Ras-GAP pleckstrin homology
(PH) domain, and speculated that this region could be the
binding site for Gβγ. However, this homology was very
weak and was not detected by others [6]. Furthermore, it
seems increasingly unlikely that PH domains function as
Gβγ-binding modules.
In considering the regulation of p101–p110γ by Gβγ, we
can learn from other Gβγ-regulated enzymes. The role
played by Gβγ subunits in directly binding to and regulat-
ing the activity and subcellular distribution of signalling
proteins is now generally appreciated. In addition to the
p101–p110γ enzyme described by Stephens et al. [6], other
effector molecules known to be regulated by direct
binding of Gβγ include the GIRK1, GIRK2 and GIRK4
subunits of inwardly rectifying G-protein regulated K+
channels, adenylyl cyclase (AC) isoforms II and IV, and
phosphatidylinositol-specific phospholipase C (PLC) β1,
β2 and β3 isoforms [14].
The prototypical Gβγ-regulated effector enzyme is the G-
protein-coupled receptor kinase 2 (GRK2), which
specifically binds to and phosphorylates agonist-occupied
G-protein-coupled receptors, thereby promoting receptor
desensitization. Upon receptor-mediated dissociation of a
heterotrimeric G-protein into Gα–GTP and Gβγ-sub-
units, the released Gβγ-subunits, which remain attached
to the plasma membrane, bind to GRK2, causing it to
translocate to the site of the activated receptor at the
plasma membrane [15]. 
Mutational analysis of GRK2 has shown that its Gβγ-
binding site includes the carboxyl-terminal region of a PH
domain, which has been found in many other signalling
proteins and initially prompted the suggestion that PH
domains may function as general Gβγ-binding domains
[16]. This is most likely not the case, as other PH domains
have a 50–100-fold lower affinity for Gβγ-subunits than
has GRK2 [17], and high-affinity binding of GRK2 to Gβγ
subunits also requires a 30 amino-acid carboxy-terminal
sequence outside of the PH domain [16]. However, a
Q613XXER sequence motif present within the carboxy-
terminal section of the GRK2 PH domain is also found in
several other Gβγ-regulated enzymes, and the Gβγ-stimu-
lated activity of AC-II, PLCβ3 and GRK2 can be reduced
in a concentration-dependent manner by a QXXER-con-
taining peptide derived from the second cytoplasmic
domain of AC-II [18].
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Although p101 confers Gβγ-sensitivity upon the
p101–p110γ dimer, it is unclear whether one or both of the
subunits binds Gβγ in vivo or in vitro [6]. Neither subunit
contains a QXXER motif, although related sequences
include Q14HALER and Q818DER in p101 and
Q922AAVER in p110γ [6]. So it is possible that binding of
Gβγ subunits to p101–p110γ may involve interactions dis-
tinct from those described for other effector enzymes. It is
also possible that p101–p110γ, together with phosducin,
phosducin-like protein and PLC-β2, all of which bind Gβγ
subunits in the absence of QXXER sequences [19,20],
uses a distinct type of Gβγ-binding site.
Without a clear understanding of the site of interaction
with Gβγ, the mechanism of activation of p110γ by p101
remains unclear. Interestingly, in the absence of Gβγ, the
specific activity of p110γ is lower in a p101–p110γ
complex than when it is a free monomer [6]. This is remi-
niscent of the p85–p110α complex, which has a lower
specific activity than free p110α. In the case of
p85–p110α, this is due in part to the ability of p110α to
phosphorylate p85 in the inter-SH2 domain (reviewed in
[7]). It is not known if a similar event occurs with
p101–p110γ, nor whether the binding of phospho-tyrosine
peptides or Gβγ counteracts this negative regulation.
From the available data, it appears that in vitro the regula-
tory subunit of PI 3-kinase represses the basal activity of
the catalytic subunit, but renders it activatable by the
appropriate allosteric regulator.
As the p101–p110γ complex is cytosolic, yet its substrate is a
membrane phospholipid, it must translocate to the plasma
membrane. Presumably, Gβγ-subunits released upon G-
protein activation bind to the p101–p110γ complex, thereby
facilitating its translocation to the plasma membrane in a
manner dependent on receptor activation. Once bound to
Gβγ, p101–p110γ is presumably activated in the manner
described by Stephens et al. [6]. In this respect, the mobi-
lization of PI 3-kinase activity closely resembles the process
by which GRK2 phosphorylates agonist-occupied G-
protein-coupled receptors — in both cases, Gbg facilitates
the translocation of the enzyme to its membrane-bound
substrate and also its activation [15]. It also parallels the
translocation/activation mechanism of p85–p110α com-
plexes by receptor tyrosine kinases, and shows that, with
respect to regulation of PI 3-kinase activity, G-protein
coupled receptors and receptor tyrosine kinases can use the
same activation mechanism — sequential enzyme translo-
cation and activation — by using distinct protein-protein
interaction domains — SH2 domains for receptor tyrosine
Figure 1
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Regulation of PI 3-kinases by receptor tyrosine kinases and G-protein
coupled receptors. The regulation of p101–p110γ and p85–p110α
and their potential downstream targets are indicated schematically.
Both PI 3-kinases have a similar, sequential ‘translocation–activation’
mechanism, but they use distinct allosteric regulators to achieve this
end. (a) Using fibroblasts as an example, p85–p110α is recruited via
the SH2 domain of p85 to the activated, phosphorylated epidermal
growth factor (EGF) receptor. This has the effect of translocating the
catalytic p110α subunit to the plasma membrane and activating it by
inducing a conformational change. (GEF, Rac GDP/GTP exchange
factor.) (b) In phagocytes, recruitment of p101–p110γ to the
membrane and activation are achieved by binding Gβγ subunits
released from trimeric G proteins after f-Met–Leu–Phe (fMLP)
receptor-mediated activation; the Gβγ -binding site and, therefore,
mechanism of activation remains to be defined.
kinases and Gβγ-binding domains for G-protein-coupled
receptors (Figure 1).
What are the downstream targets of p101–p110γ in
phagocytes? In fibroblasts, PI 3-kinases act upstream of
members of the Rac family of monomeric GTPases, which
regulate the actin cytoskeleton so as to cause membrane
ruffles [21]. Rac is also involved in assembly of the
NADPH oxidase [1] by binding to one of the cytosolic
components of the enzyme complex, p67phox (Figure 1).
These observations are consistent with a model in which
activation of p101–p110g in turn promotes activation of
Rac, perhaps by stimulating a Rac GDP/GTP exchange
factor, and thereby assembly of the oxidase complex. 
Recent studies have indicated that the canonical PI 3-
kinases act upstream of a kinase cascade which regulates
the activity of PKB/c-Akt, a serine/threonine kinase impli-
cated in promoting cell survival [5]. Although it is possible
that PKB may also be a downstream target of p101–p110γ
in phagocytes, an alternative possibility is that PI(3,4,5)P3
may activate another kinase which serves to phosphorylate
p47phox, the other cytosolic NADPH oxidase component
known to be phosphorylated in a PI 3-kinase-dependent
manner [22] (Figure 1). Elucidation of the precise role of
p101–p110γ in these processes may be facilitated by the
generation of suitable gene ‘knockout’ or transgenic mice.
The PI 3-kinase subunits p101 and p110γ appear to be
particularly abundant in leukocytes (A. Eguinoa, P.
Hawkins and L. Stephens, personal communication), in
contrast to the canonical forms of PI 3-kinase, which have
a broader distribution. It is already known that PI 3-kinase
catalyses a rate-limiting step in phagocyte activation [3,4],
and the novel properties discussed above make
p101–p110γ an attractive target for attempts to discover
new anti-inflammatory drugs that work by selectively
inhibiting PI 3-kinase-dependent phagocyte activation.
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